Peptide directoryGut, pancreas & liver

Oxyntomodulin

One gut peptide that speaks to both the GLP-1 and the glucagon receptor.

Where it comes from

Made in
L cells of the lower gut
Sent out by
After a meal, in proportion to its size; rises greatly after gastric bypass
Acts on
  • Hypothalamus
  • Pancreas
  • Liver

What it does

  • Reduces appetite and food intake 1
  • Raises energy expenditure 1
  • Lowers glucose through insulin release

In medicine

  • No medicine is oxyntomodulin itself; infusions cut food intake and weight in short randomised trials in overweight volunteers 1
  • Its surge after bariatric surgery is part of why appetite falls afterwards, and its blood level tracks how far that appetite falls 2

Beyond the body’s own use

  • It is the template for the GLP-1/glucagon dual agonists: mazdutide took off 16.7% of body weight in a Chinese phase 3 trial 3 and is approved there for weight management, survodutide is in phase 3 for obesity and fatty liver disease, and cotadutide was dropped
  • Infused into volunteers four days running it both cut energy intake and raised energy expenditure, which is the finding the whole dual-agonist idea rests on 1
  • Oxyntomodulin itself lasts minutes in blood, so it is given only by infusion in a study; the medicines built from it are engineered to last a week

Sources

  1. Wynne et al., Oxyntomodulin increases energy expenditure and decreases energy intake, International Journal of Obesity 2006
  2. Perakakis et al., The role of glicentin and oxyntomodulin in human metabolism, Journal of Clinical Endocrinology and Metabolism 2020
  3. Gao et al., Mazdutide for weight reduction in Chinese adults with obesity (GLORY-2), JAMA 2026

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.